Application of Jian indigo naturalis in preparation of medicine for treating ulcerative colitis

Abstract

The invention provides application of Jian indigo naturalis in preparation of medicine for treating ulcerative colitis. The result shows that the clinical response, clinical remission and mucous membrane healing effects of the single Jian indigo naturalis after oral administration for 8 weeks are satisfactory, and the Jian indigo naturalis has a good curative effect on hormone-dependent or anti-TNF-alpha refractory UC. Clinical tests and animal experiments show that the Jian indigo naturalis has a good curative effect, is convenient for administration, the ulcerative colitis can be effectivelytreated; no severe adverse reactions, the Jian indigo naturalis can be orally taken to quickly relieve hematochezia; the clinical response rate, the clinical remission rate and the mucous membrane healing rate are higher than those of a placebo group; meanwhile, animal experiments also prove that the Jian indigo naturalis can effectively reduce the disease activity index of model animals, maintain animal weight, improve colon pathological injury, reduce the serum pro-inflammatory factor level, inhibit activation of related inflammatory signal channels and promote mucosal healing, and has goodclinical application prospects.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of Jianqingdai in the preparation of medicines for treating ulcerative colitis. Background technique [0002] Ulcerative colitis is a non-specific inflammatory bowel disease, which is called idiopathic colitis by the World Health Organization. It is a chronic nonspecific inflammatory process of unknown etiology limited to the colonic mucosa and submucosa. The lesions are mostly located in the sigmoid colon and rectum, and can also extend to the descending colon or even the entire colon. The disease mostly occurs in young adults aged 20 to 40 years old. With the changes in diet structure, living habits and rhythm of life, and the improvement of diagnostic methods, in recent years, the incidence of elderly patients has an upward trend. The disease persists for a long time, and there is a potential risk of malignant transformation. The main clinical manifestation...

AI Technical Summary

Problems solved by technology

It is known that mesalamine granules, the first-line drug for UC, are pH-dependent preparations, mainly released in the terminal ileum, and the concentration in the colon gradually decreases from near to far. Therefore, for the rectal type (E1), the left colon (E2, usually rectal B colon type) is less effective, and the proportion of these two types of patients in UC is higher, often need to be combined with mesalamine suppository anal plug and mesalamine enema treatment, which will increase the treatment intolerance and economic burden for patients

Images